Gentamicin Inj

Compare Gentamicin Inj  to:
Compare
Compare

Generic Name for Gentamicin Inj

Gentamicin sulfate 40mg/mL; IM, or IV inj after dilution; contains sulfites.

Legal Classification:

Rx

Pharmacological Class for Gentamicin Inj

Aminoglycoside.

Manufacturer of Gentamicin Inj

Various generic manufacturers

Indications for Gentamicin Inj

Serious susceptible infections.

Adult dose for Gentamicin Inj

Obesity: Base dose on lean body mass. Usual duration 7–10 days. 1mg/kg IM or IV every 8 hours; max 5mg/kg/day. For alternative dosing regimens (eg, extended intervals) see literature.

Children's dosing for Gentamicin Inj

Premature and infants <1 week: 2.5mg/kg every 12 hours. Neonates: 2.5mg/kg every 8 hours. Others: 2–2.5mg/kg every 8 hours.

Precautions for Gentamicin Inj

Monitor for nephro- and neurotoxicity; avoid peak serum levels >12micrograms/mL (when dosed at conventional intervals) and trough levels >2micrograms/mL. Renal impairment: reduce dose, see literature; maintain adequate hydration. Prolonged use or excessive doses. Asthma. Neuromuscular disorders. Elderly. Pregnancy (Cat.D): not recommended.

Interactions for Gentamicin Inj

Avoid concomitant furosemide, ethacrynic acid, other nephro/neurotoxic drugs including cephalosporins. May potentiate neuromuscular blockade.

Adverse Reactions for Gentamicin Inj

Nephro- or neurotoxicity, respiratory depression, lethargy, confusion, depression, visual disturbances, elevated liver enzymes, blood dyscrasias.

How is Gentamicin Inj supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Related Resources

Cayston inhaled antibiotic approved for cystic fibrosis

February 23, 2010

The FDA has approved Cayston (aztreonam for inhalation solution, from Gilead Sciences) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa.

Phase 3 study of fidaxomicin for clostridium difficile infection (CDI)

February 05, 2010

Optimer Pharmaceuticals announced positive top-line results from the second of two Phase 3 trials evaluating the safety and efficacy of fidaxomicin (OPT-80) in patients with Clostridium difficile Infection (CDI).

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of Arikace for treatment of pseudomonas lung infections

October 19, 2009

Transave reported additional positive clinical trial results on its lead investigational drug, Arikace (liposomal amikacin for inhalation), an antibiotic to treat chronic lung infections.

Vibativ approved for complicated skin and skin structure infections

September 18, 2009

The FDA has approved Vibativ (telavancin, from Theravance and Astellas), a bactericidal, once-daily injectable lipoglycopeptide antibiotic.